We are a Specialty Pharmaceutical Company with a Focus in Pain and Addiction

BEMA® Technology

A small, dissolvable polymer film for application to mucosal membranes (inner lining of cheek) which allows for transmucosal delivery of drugs.

 

CURRENT INVESTOR PRESENTATION, DATED 4-5-15

 

Upcoming Conferences Dr. Mark Sirgo Presenting at:

Deutsche Bank Securities, Thursday, May 7, 2015 at 12:50 p.m. ET

Bank of America Merrill Lynch, Tuesday, May 12, 2015 at 5:00 p.m. PT

 

_______________________

Webcast: Clonidine Topical Gel Phase 3 Study Preliminary Results

Monday, March 30, at 8:00 a.m. ET (5:00 a.m. Pacific Time)

 

 CLICK HERE FOR CLONIDINE SLIDES

 

Webcast:   http://edge.media-server.com/m/p/j77ikhvk

____________________________

BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Year-end 2014 Financial Results

Monday, March 16, 2015 @ 5pm Eastern/2:00pm Pacific

Replay of call:

                       Domestic:            877-870-5176

                       International:   858-384-5517    

                       Conference ID:  1385073

  
____________________________________

Get the latest details on our products and services.

Top News

BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development
Previously announced interim data showed pain improvement compared to placebo; results not replicated in patients enrolled post interim analysis


BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Year-End 2014 Financial Results
2014 - A Year of Many Significant Milestones, with More Expected for 2015, as BDSI Continues its Growth as an Integrated Specialty Pharmaceutical Company